Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Biogen is advancing its Alzheimer's drug to a late-stage trial despite disappointing data, with signals suggesting the treatment decreases levels of tau and slows cognitive decline. The treatment appears to be most effective at the lowest dose. This development is a significant step in the search for an effective Alzheimer's treatment.